News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Eisai Company, Ltd. Announce Japan Launch of Oral Anticoagulant Warfarin Granules 0.2%
December 5, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo, Nov 30, 2011 (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch Warfarin Granules 0.2%, a new formulation of the company's oral anti-coagulant Warfarin (warfarin potassium), on December 1 in Japan.
Twitter
LinkedIn
Facebook
Email
Print
Asia
MORE ON THIS TOPIC
Cancer
Summit, Akeso’s Keytruda Challenger Wins Chinese OK as US Approval Questions Linger
April 28, 2025
·
3 min read
·
Tristan Manalac
Lung cancer
Summit’s Bispecific Beats Yet Another Cancer Med, Pressuring Keytruda’s ‘Supremacy’
April 23, 2025
·
2 min read
·
Tristan Manalac
Government
Lawmakers Seek to Boost US Biotech Sector, Keep China’s Growth in Check
April 11, 2025
·
2 min read
·
Tristan Manalac
China
Amid Trade Tensions, Commission Warns China is ‘Dangerously Close’ to Overtaking US Biotech
April 9, 2025
·
2 min read
·
Tristan Manalac
